ClinicalTrials.gg
RecruitingNCT07064473Updated Nov 12, 2026

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

A Phase 3 interventional study of Vicadrostat and Empagliflozin in Diabetes Mellitus, Type 2, Hypertension and Cardiovascular Diseases, sponsored by Boehringer Ingelheim. Recruiting at 1,142 sites in 51 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 12, 2026Site recruiting status changed14 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Planned enrollment
Largest of 96
11,800 · median 302
Started
2025
the only one that year
Phase 3
50 of 130
2 open now
Registered
129th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one has the largest planned enrollment of the 96 interventional ones that give a count, is the only one that started in 2025, is one of 50 in phase 3, and was the 129th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.

Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.

Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.

Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old at time of consent
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial
  • Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2).
  • Participants with medical history of hypertension and on active pharmacological treatment
  • Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment
  • Established cardiovascular (CV) disease and on active pharmacological treatment
  • At least one additional risk factor for developing heart failure (HF)

Exclusion criteria

Exclusion Criteria:

  • History of HF or hospitalization for HF or treatment of HF
  • Atrial fibrillation or Atrial flutter with a resting heart rate >110 beats per minute (bpm) documented by echocardiogram () at Visit 1 (screening)
  • Advanced untreated conduction disease or untreated ventricular arrhythmia at Visit 1 (screening)
  • Treatment with an Mineralocorticoid receptor antagonist (MRA)
  • Treatment with amiloride or other potassium-sparing diuretic
  • Receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomisation), or planned during the trial:

    • A direct renin inhibitor (e.g. aliskiren)
    • More than one Angiotensin-converting enzyme inhibitor (ACEi) and/or Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously
    • Other aldosterone synthase inhibitors (e.g. baxdrostat)
    • Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11,800 participants (estimated)

Study arms

  • Experimental
    Vicadrostat + empagliflozin treatment arm

    Drug: Vicadrostat · Drug: Empagliflozin

  • Active comparator
    Vicadrostat-placebo + empagliflozin treatment arm

    Drug: Empagliflozin · Drug: Placebo matching Vicadrostat

Interventions

  • Vicadrostat

    Also known as: BI 690517

  • Empagliflozin

  • DrugPlacebo matching Vicadrostat

    Placebo matching Vicadrostat

06

What researchers measure

Primary outcomes

  1. Time to first event of cardiovascular (CV) death or heart failure event (HFE)

    Time frame: Up to 51 months

Secondary outcomes

  1. Time to first event of cardiovascular (CV) death or hospitalisation for heart failure (HHF)

    Time frame: Up to 51 months

  2. Absolute change from baseline in mean systolic blood pressure (SBP) [mmHg] at Week 24

    Time frame: At baseline and week 24

  3. Relative change from baseline in Urine Albumin Creatinine Ratio (UACR) [mg/g] at Week 24

    Time frame: At baseline and week 24

  4. Time to first occurrence of the composite outcome of kidney disease progression, HHF, CV death

    Time frame: Up to 51 months

  5. Time to first event of CV death, HFE, non-fatal myocardial infarction (MI) or non-fatal stroke (4-point Major adverse cardiovascular events (MACE))

    Time frame: Up to 51 months

  6. Occurrences of all-cause hospitalisations (first and recurrent)

    Time frame: Up to 51 months

  7. Time to first event of new-onset atrial fibrillation or atrial flutter (in participants without history of atrial fibrillation and atrial flutter) or CV death

    Time frame: Up to 51 months

  8. Time to all-cause death

    Time frame: Up to 51 months

  9. Time to CV death

    Time frame: Up to 51 months

  10. Time to first HHF

    Time frame: Up to 51 months

  11. Time to first event of new-onset HF or CV death

    Time frame: Up to 51 months

  12. Occurrences of HHF (first and recurrent)

    Time frame: Up to 51 months

  13. Absolute change from baseline in mean diastolic blood pressure (DBP) [mmHg] at Week 24

    Time frame: At baseline and week 24

07

Study locations

1,093 of 1,142 sites recruiting

Showing the first 100 of 1,142 sites across 51 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 52 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 52 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 14, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Dec 14, 2029
CompletionEst.
Dec 21, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 15 sites removed. 18 sites changed recruiting status (9 now completed, 9 now recruiting)
Show 18 sites
  • Aspirus Research Institute · Wausau, United StatesRecruiting→Completed
  • Azienda Socio Sanitaria Territoriale Di Monza · Monza (MB), ItalyNot yet recruiting→Recruiting
  • Kyoto University Hospital · Kyoto, Kyoto, JapanNot yet recruiting→Recruiting
  • Södertälje Sjukhus · Södertälje, SwedenNot yet recruiting→Recruiting
  • HOP Est Francilien · Jossigny, FranceRecruiting→Completed
  • HOP Civil · Strasbourg, FranceRecruiting→Completed
  • University General Hospital Attikon · Chaïdári, GreeceNot yet recruiting→Recruiting
  • Max Super Specialty Hospital, Saket · Sāket, IndiaNot yet recruiting→Recruiting
  • Unidade Local de Saúde de Matosinhos · Matosinhos Municipality, PortugalRecruiting→Completed
  • ULS do Estuário do Tejo · Vila Franca de Xira, PortugalRecruiting→Completed
  • King Faisal Specialist Hospital and Research Center · Riyadh, Saudi ArabiaNot yet recruiting→Recruiting
  • Region Vaesternorrland · Sundsvall, SwedenRecruiting→Completed
  • Taipei Veterans General Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
  • Institute of Cardiovascular Diseases of Vojvodine · Kamenitz, SerbiaNot yet recruiting→Recruiting
  • Hanoi Medical University · Hanoi, VietnamNot yet recruiting→Recruiting
  • McGill University Health Centre (MUHC) · Montreal, CanadaRecruiting→Completed
  • Clinical Trials Services s.r.o · Uherské Hradiště, CzechiaRecruiting→Completed
  • HOP Haguenau · Haguenau, FranceRecruiting→Completed
Show 14 added (4 Germany, 1 United States, 1 Brazil, 1 China, 1 Sweden, 1 Argentina, 1 Serbia, 1 France, 1 Italy, 1 Portugal, 1 Spain)
  • Tribe Clinical Research LLC - Greenville · Greenville, United States
  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
  • Sichuan Provincial People's Hospital · Chengdu, China
  • Klinisches Forschungszentrum Dr. Hagemann am Hausarztzentrum am Germaniaplatz · Essen, Germany
  • Zentrum für Klinische Forschung · Wangen, Germany
  • Sahlgrenska Universitetssjukhuset, Östra · Gothenburg, Sweden
  • CICEMO · CABA, Argentina
  • Cardio Centrum Ludwigsburg Bietigheim · Ludwigsburg, Germany
  • Institute of Cardiovascular Diseases of Vojvodine · Kamenitz, Serbia
  • HOP Haut-Leveque · Pessac, France
  • Azienda Socio Sanitaria Ligure 2 · Savona, Italy
  • Herz und Diabeteszentrum NRW Bad Oeynhausen Universitätsklinik der Ruhr-Universität Bochum · Bad Oeynhausen, Germany
  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 15 removed
  • Tribe Clinical Research LLC · Greenville, United States
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil
  • People's Hospital of Sichuan Province · Chengdu, China
  • Klinisches Forschungszentrum Dr. Hagemann · Essen, Germany
  • Zentrum für Klinische Forschung Wangen · Wangen, Germany
  • Rabindranath Tagore International Institute of Cardiac Sciences · Kolkata, India
  • Sahlgrenska Universitetssjukhuset, Ostra · Gothenburg, Sweden
  • Consultorio de Investigacion Clinica EMO SRL · Ciudad Autonoma de Buenos Aire, Argentina
  • Cardio Centrum Ludwigsburg Bietigheim CCLB · Ludwigsburg, Germany
  • Institute of Cardiovascular Diseases of Vojvodine · Sremska Mitrovica, Serbia
  • HOP Haut-Lévêque · Pessac, France
  • Azienda Sociosanitaria Ligure 2 · Savona, Italy
  • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen · Bad Oeynhausen, Germany
  • ULS de Santa Maria, E.P.E · Lisbon, Portugal
  • Hospital Virgen del Rocio · Seville, Spain
across 4 updates, Sep 30, 2026 – Nov 12, 2026
Site contacts
Changed at 10 sites. See the sites
Show 10 sites
  • Aspirus Research Institute · Wausau, United StatesContact removed u•••@bitrialsupport.com · •••2368
  • HOP Est Francilien · Jossigny, FranceContact removed f•••@bitrialsupport.com · •••2354
  • HOP Civil · Strasbourg, FranceContact removed f•••@bitrialsupport.com · •••2354
  • Apollo Multispeciality Hospitals Limited · Kolkata, IndiaContact removed i•••@bitrialsupport.com · •••1442
  • Unidade Local de Saúde de Matosinhos · Matosinhos Municipality, PortugalContact removed p•••@bitrialsupport.com · •••6070
  • ULS do Estuário do Tejo · Vila Franca de Xira, PortugalContact removed p•••@bitrialsupport.com · •••6070
  • Region Vaesternorrland · Sundsvall, SwedenContact removed s•••@bitrialsupport.com · •••0001
  • McGill University Health Centre (MUHC) · Montreal, CanadaContact removed c•••@bitrialsupport.com · •••2346
  • Clinical Trials Services s.r.o · Uherské Hradiště, CzechiaContact removed s•••@bitrialsupport.com · •••0048
  • HOP Haguenau · Haguenau, FranceContact removed f•••@bitrialsupport.com · •••2354
across 4 updates, Sep 30, 2026 – Nov 12, 2026
Show all 4 updates
  1. Nov 12, 2026
    3 sites added, 3 sites removed. 3 sites changed recruiting status (3 now completed)
    Show 3 sites
    • McGill University Health Centre (MUHC) · Montreal, CanadaRecruiting→Completed
    • Clinical Trials Services s.r.o · Uherské Hradiště, CzechiaRecruiting→Completed
    • HOP Haguenau · Haguenau, FranceRecruiting→Completed
    Show 3 added (1 Germany, 1 Portugal, 1 Spain)
    • Herz und Diabeteszentrum NRW Bad Oeynhausen Universitätsklinik der Ruhr-Universität Bochum · Bad Oeynhausen, Germany
    • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 3 removed
    • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen · Bad Oeynhausen, Germany
    • ULS de Santa Maria, E.P.E · Lisbon, Portugal
    • Hospital Virgen del Rocio · Seville, Spain
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • McGill University Health Centre (MUHC) · Montreal, CanadaContact removed c•••@bitrialsupport.com · •••2346
    • Clinical Trials Services s.r.o · Uherské Hradiště, CzechiaContact removed s•••@bitrialsupport.com · •••0048
    • HOP Haguenau · Haguenau, FranceContact removed f•••@bitrialsupport.com · •••2354
    + 1 other change: verification date
  2. Oct 28, 2026
    2 sites added, 2 sites removed. 3 sites changed recruiting status (2 now recruiting, 1 now suspended)
    Show 3 sites
    • Apollo Multispeciality Hospitals Limited · Kolkata, IndiaRecruiting→Suspended
    • Institute of Cardiovascular Diseases of Vojvodine · Kamenitz, SerbiaNot yet recruiting→Recruiting
    • Hanoi Medical University · Hanoi, VietnamNot yet recruiting→Recruiting
    Show 2 added (1 France, 1 Italy)
    • HOP Haut-Leveque · Pessac, France
    • Azienda Socio Sanitaria Ligure 2 · Savona, Italy
    Show 2 removed
    • HOP Haut-Lévêque · Pessac, France
    • Azienda Sociosanitaria Ligure 2 · Savona, Italy
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Apollo Multispeciality Hospitals Limited · Kolkata, IndiaContact removed i•••@bitrialsupport.com · •••1442
  3. Oct 14, 2026
    3 sites added, 3 sites removed. 10 sites changed recruiting status (5 now completed, 5 now recruiting)
    Show 10 sites
    • HOP Est Francilien · Jossigny, FranceRecruiting→Completed
    • HOP Civil · Strasbourg, FranceRecruiting→Completed
    • University General Hospital Attikon · Chaïdári, GreeceNot yet recruiting→Recruiting
    • Apollo Multispeciality Hospitals Limited · Kolkata, IndiaSuspended→Recruiting
    • Max Super Specialty Hospital, Saket · Sāket, IndiaNot yet recruiting→Recruiting
    • Unidade Local de Saúde de Matosinhos · Matosinhos Municipality, PortugalRecruiting→Completed
    • ULS do Estuário do Tejo · Vila Franca de Xira, PortugalRecruiting→Completed
    • King Faisal Specialist Hospital and Research Center · Riyadh, Saudi ArabiaNot yet recruiting→Recruiting
    • Region Vaesternorrland · Sundsvall, SwedenRecruiting→Completed
    • Taipei Veterans General Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
    Show 3 added (1 Argentina, 1 Germany, 1 Serbia)
    • CICEMO · CABA, Argentina
    • Cardio Centrum Ludwigsburg Bietigheim · Ludwigsburg, Germany
    • Institute of Cardiovascular Diseases of Vojvodine · Kamenitz, Serbia
    Show 3 removed
    • Consultorio de Investigacion Clinica EMO SRL · Ciudad Autonoma de Buenos Aire, Argentina
    • Cardio Centrum Ludwigsburg Bietigheim CCLB · Ludwigsburg, Germany
    • Institute of Cardiovascular Diseases of Vojvodine · Sremska Mitrovica, Serbia
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • HOP Est Francilien · Jossigny, FranceContact removed f•••@bitrialsupport.com · •••2354
    • HOP Civil · Strasbourg, FranceContact removed f•••@bitrialsupport.com · •••2354
    • Apollo Multispeciality Hospitals Limited · Kolkata, IndiaContact added i•••@bitrialsupport.com · •••1442
    • Unidade Local de Saúde de Matosinhos · Matosinhos Municipality, PortugalContact removed p•••@bitrialsupport.com · •••6070
    • ULS do Estuário do Tejo · Vila Franca de Xira, PortugalContact removed p•••@bitrialsupport.com · •••6070
    • Region Vaesternorrland · Sundsvall, SwedenContact removed s•••@bitrialsupport.com · •••0001
    + 1 other change: verification date
  4. Sep 30, 2026
    6 sites added, 7 sites removed. 4 sites changed recruiting status (3 now recruiting, 1 now completed)
    Show 4 sites
    • Aspirus Research Institute · Wausau, United StatesRecruiting→Completed
    • Azienda Socio Sanitaria Territoriale Di Monza · Monza (MB), ItalyNot yet recruiting→Recruiting
    • Kyoto University Hospital · Kyoto, Kyoto, JapanNot yet recruiting→Recruiting
    • Södertälje Sjukhus · Södertälje, SwedenNot yet recruiting→Recruiting
    Show 6 added (2 Germany, 1 United States, 1 Brazil, 1 China, 1 Sweden)
    • Tribe Clinical Research LLC - Greenville · Greenville, United States
    • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
    • Sichuan Provincial People's Hospital · Chengdu, China
    • Klinisches Forschungszentrum Dr. Hagemann am Hausarztzentrum am Germaniaplatz · Essen, Germany
    • Zentrum für Klinische Forschung · Wangen, Germany
    • Sahlgrenska Universitetssjukhuset, Östra · Gothenburg, Sweden
    Show 7 removed
    • Tribe Clinical Research LLC · Greenville, United States
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil
    • People's Hospital of Sichuan Province · Chengdu, China
    • Klinisches Forschungszentrum Dr. Hagemann · Essen, Germany
    • Zentrum für Klinische Forschung Wangen · Wangen, Germany
    • Rabindranath Tagore International Institute of Cardiac Sciences · Kolkata, India
    • Sahlgrenska Universitetssjukhuset, Ostra · Gothenburg, Sweden
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Aspirus Research Institute · Wausau, United StatesContact removed u•••@bitrialsupport.com · •••2368

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07064473
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jul 22, 2025
Primary completion
Dec 14, 2029 (estimated)
Completion
Dec 21, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vicadrostat

Start the discussion